Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
JNJ Price Action
Last 7 days
0.5%
Last 30 days
8.9%
Last 90 days
13.5%
Trailing 12 Months
17.8%
JNJ Stock Price
JNJ RSI Chart
JNJ Valuation
JNJ Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
JNJ Fundamentals
JNJ Revenue
JNJ Earnings
JNJ Profitability
JNJ Investor Care
JNJ Alerts
The Good News
Johnson & Johnson (JNJ) reported impressive Q3 earnings with a significant revenue increase and raised sales guidance for 2025, indicating strong business resilience (Sources: Zacks). Jamison Private Wealth Management's substantial investment reflects confidence in JNJ's growth prospects (Sources: The Motley Fool). Furthermore, analysts from several firms maintain buy ratings with positive price targets, underscoring the stock's favorable outlook (Sources: The Globe and Mail).
The Bad News
Johnson & Johnson (JNJ) is facing significant legal challenges, including a major lawsuit in the U.K. over alleged asbestos in baby powder, which could lead to substantial damages (Sources: Benzinga). Additionally, insider selling raises concerns about management's confidence, despite positive analyst ratings (Sources: The Globe and Mail).
Revenue & Growth
Revenue Breakdown
As of: Jun 30, 2025
Innovative Medicine
| |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 89.3B | 90.6B | 0 | 0 |
| 2024 | 85.6B | 86.6B | 87.7B | 88.8B |
| 2023 | 81.0B | 82.3B | 83.7B | 85.2B |
| 2022 | 76.3B | 73.2B | 69.8B | 80.0B |
| 2021 | 84.2B | 89.2B | 91.4B | 78.7B |
| 2020 | 82.7B | 80.5B | 80.9B | 82.6B |
| 2019 | 81.6B | 81.3B | 81.7B | 82.1B |
| 2018 | 78.7B | 80.7B | 81.4B | 81.6B |
| 2017 | 72.2B | 72.5B | 74.4B | 76.5B |
| 2016 | 70.2B | 70.9B | 71.6B | 71.9B |
| 2015 | 73.6B | 71.9B | 70.5B | 70.1B |
| 2014 | 71.9B | 73.5B | 74.4B | 74.3B |
| 2013 | 68.6B | 70.0B | 70.5B | 71.3B |
| 2012 | 65.0B | 64.9B | 65.9B | 67.2B |
| 2011 | 62.1B | 63.4B | 64.4B | 65.0B |
| 2010 | 62.5B | 62.6B | 62.5B | 61.6B |
| 2009 | 62.6B | 61.4B | 60.5B | 61.9B |
| 2008 | 0 | 62.0B | 62.9B | 63.7B |
| 2007 | 0 | 0 | 0 | 61.1B |
Get all data in R, Python etc through our Historical Stock Data APIs
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
| CEO | Mr. Joaquin Duato |
|---|---|
| WEBSITE | jnj.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers General |
| EMPLOYEES | 65535 |
